(WSJ) – Long a maker of low-end generic drugs, the country is now home to biotech firms that are innovating fast

Today Eli Lilly and Novo Nordisk, with drugs like Mounjaro and Ozempic, are the undisputed leaders of the $80-billion global GLP-1 market, which is dominated by U.S. sales.

But Chinese biotechs are pouring in, hoping to steal a slice of the weight-loss drug market. There are currently nearly 250 Chinese competitors in the research pipeline, according to data provider PharmCube. More than 20 of those treatments are already licensed overseas. (Read More)